

Table of Contents

Number	Title
1	Table 00: Comments
2	Table 01: Study population and enrolment information
3	Table 02: Patients by region, country, and cohort
4	Table 03 : Demographic Characteristics
5	Table 04 : Care setting , Type of AF and Insurance
6	Table 05 : Vital signs and life style
7	Table 06 : Clinical History
8	Table 07 : Treatment for stroke prophylaxis
9	Table 08: Treatment
10	Table 09 : Risk scores
11	Table 10: Treatment at baseline by CHA2DS2-VASc score
12	Table 11: Treatment at baseline by HAS-BLED score
13	Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
14	Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
15	Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
16	Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
17	Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
18	Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
19	Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4

Table 00: Comments

- 1 The data was extracted from the GARFIELD-AF registry database on 28 JUL 2016
- 2 The data includes retrospective patients in cohort 1 and prospective patients in cohort 1, 2, 3, 4 and 5
- 3 The variable 'Congestive heart failure' was split into 'History of CHF' and 'Current CHF' in cohorts 3, 4 and 5. History of and/or current CHF were used to identify CHF in cohort 3, 4 and 5 patients (Table 6)
- 4 The variable 'Coronary artery disease' was split into 'History of CAD' and 'Current CAD' in cohorts 3, 4 and 5. History of and/or current CAD were used to identify CAD in cohort 3, 4 and 5 patients (Table 6)
- 5 The variable 'Other thromboembolism' is not recorded for patients in cohort 3, 4 and 5
- 6 The option 'None' was added in the CRF for the 'Chronic renal disease' field in cohort 3, 4 and 5. The percentages for the variable 'Moderate to severe CKD' are estimated assuming that patients with 'unknown' stage of CKD are without 'Moderate to severe CKD' (Table 6)
- 7 Table 7 describes the baseline treatment for stroke prophylaxis. For each treatment group identifier options are mutually exclusive. The option 'unknown' includes combination of treatments
- 8 Table 8 shows the baseline treatment for stroke prophylaxis with non mutually exclusive groups
- 9 Table 12 shows INR values and TTR for patients treated with VKA±AP at baseline. INR readings during the first year of follow-up were included in the analysis. Values less than 0.8 or greater than 20 were removed since these values may not be plausible. Patients on VKA±AP at enrolment but with fewer than three readings during the follow-up were excluded from the analysis. Patient-level TTR was estimated by linear interpolation according to Rosendaal et al (1993), using 2.0-3.0 as the target INR range. TTR was estimated using INR readings until discontinuation or interruption of VKA or the end of follow-up. In addition, TTR was estimated between two consecutive INR readings only if the interval did not exceed 90 days.
- 10 Tables 13 and 14 describe events during the first year of follow-up for patients in cohorts 1-4. Only the first occurrence of each event was taken into account.
- 11 Table 13 Congestive heart failure during the follow-up includes new congestive heart failure or worsening of pre-existing congestive heart failure.

Table 01: Study population and enrolment information
Full Analysis Dataset : INDIA

Number of prospective patients (C1+C2+C3+C4+C5)	1312
Number of enrolling sites	26
Number of enrolling countries	1
Enrolment period	01AUG2012 - 26JUL2016
Duration of enrolment (months)	47.8

**Table 02: Patients by region, country, and cohort
Full Analysis Dataset : INDIA**

Region	Country	Cohort 2 (N=317)	Cohort 3 (N=334)	Cohort 4 (N=241)	Cohort 5 (N=420)	Total Prospective patients Cohorts 1 to 5 (N=1312)	Total Prospective patients Cohorts 1 to 4 (N=892)
Asia	India	317	334	241	420	1312	892

**Table 03 : Demographic Characteristics
Full Analysis Dataset : INDIA**

Variable	Statistics	Cohort 2 (N=317) (n %)	Cohort 3 (N=334) (n %)	Cohort 4 (N=241) (n %)	Cohort 5 (N=420) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1312)	Total Prospective patients Cohorts 1 to 4 (N=892)
Sex, n(%)	n (missing)	317 (0)	334 (0)	241 (0)	420 (0)	1312 (0)	892 (0)
	Male	185 (58.4)	200 (59.9)	149 (61.8)	245 (58.3)	779 (59.4)	534 (59.9)
	Female	132 (41.6)	134 (40.1)	92 (38.2)	175 (41.7)	533 (40.6)	358 (40.1)
Age at Diagnosis (Years)	n (missing)	317 (0)	334 (0)	241 (0)	420 (0)	1312 (0)	892 (0)
	Mean (SD)	65.2 (12.5)	66.6 (12.0)	65.2 (12.2)	66.2 (11.8)	65.9 (12.1)	65.7 (12.3)
	Median (IQR)	65.0 (58.0 to 75.0)	67.0 (60.0 to 75.0)	66.0 (58.0 to 74.0)	67.0 (59.0 to 75.0)	67.0 (59.0 to 75.0)	66.0 (58.0 to 75.0)
	Min to Max	23 to 91	19 to 91	28 to 90	23 to 93	19 to 93	19 to 91
Age Group, n(%)	n (missing)	317 (0)	334 (0)	241 (0)	420 (0)	1312 (0)	892 (0)
	<65	148 (46.7)	129 (38.6)	107 (44.4)	169 (40.2)	553 (42.1)	384 (43.0)
	65-74	83 (26.2)	112 (33.5)	80 (33.2)	135 (32.1)	410 (31.3)	275 (30.8)
	>=75	86 (27.1)	93 (27.8)	54 (22.4)	116 (27.6)	349 (26.6)	233 (26.1)
Time since AF Diagnosis (Weeks)	n (missing)	217 (100)	203 (131)	123 (118)	225 (195)	768 (544)	543 (349)
	Mean (SD)	1.75 (1.59)	1.19 (1.49)	1.18 (1.48)	1.27 (1.52)	1.37 (1.54)	1.42 (1.55)
	Median (IQR)	1.20 (0.40 to 2.80)	0.50 (0.20 to 1.40)	0.50 (0.10 to 1.70)	0.50 (0.20 to 1.70)	0.70 (0.20 to 2.00)	0.80 (0.20 to 2.10)
	Min to Max	0.1 to 6.0	0.1 to 6.0	0.1 to 5.4	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0
Race, n(%)	n (missing)	317 (0)	334 (0)	241 (0)	420 (0)	1312 (0)	892 (0)
	Caucasian	1 (0.3)	-	2 (0.8)	3 (0.7)	6 (0.5)	3 (0.3)
	Asian (Not Chinese)	316 (99.7)	334 (100.0)	239 (99.2)	416 (99.0)	1305 (99.5)	889 (99.7)
	Mixed/Other	-	-	-	1 (0.2)	1 (0.1)	-

**Table 03 : Demographic Characteristics
Full Analysis Dataset : INDIA**

Variable	Statistics	Cohort 2 (N=317) (n %)	Cohort 3 (N=334) (n %)	Cohort 4 (N=241) (n %)	Cohort 5 (N=420) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1312)	Total Prospective patients Cohorts 1 to 4 (N=892)
Region, n(%)	n (missing)	317 (0)	334 (0)	241 (0)	420 (0)	1312 (0)	892 (0)
	Asia	317 (100.0)	334 (100.0)	241 (100.0)	420 (100.0)	1312 (100.0)	892 (100.0)

**Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : INDIA**

Variable	Statistics	Cohort 2 (N=317) (n %)	Cohort 3 (N=334) (n %)	Cohort 4 (N=241) (n %)	Cohort 5 (N=420) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1312)	Total Prospective patients Cohorts 1 to 4 (N=892)
Care Setting Speciality at Diagnosis, n(%)	n (missing)	317 (0)	334 (0)	241 (0)	420 (0)	1312 (0)	892 (0)
	Internal Medicine	59 (18.6)	58 (17.4)	36 (14.9)	46 (11.0)	199 (15.2)	153 (17.2)
	Cardiology	251 (79.2)	270 (80.8)	193 (80.1)	356 (84.8)	1070 (81.6)	714 (80.0)
	Neurology	3 (0.9)	3 (0.9)	2 (0.8)	7 (1.7)	15 (1.1)	8 (0.9)
	Geriatrics	-	-	2 (0.8)	2 (0.5)	4 (0.3)	2 (0.2)
	Primary Care/General Practice	4 (1.3)	3 (0.9)	8 (3.3)	9 (2.1)	24 (1.8)	15 (1.7)
Care Setting Location at Diagnosis, n(%)	n (missing)	317 (0)	334 (0)	241 (0)	420 (0)	1312 (0)	892 (0)
	Hospital	298 (94.0)	296 (88.6)	217 (90.0)	388 (92.4)	1199 (91.4)	811 (90.9)
	Office	14 (4.4)	18 (5.4)	19 (7.9)	23 (5.5)	74 (5.6)	51 (5.7)
	Anticoagulation clinic/thrombosi s centre	1 (0.3)	1 (0.3)	-	-	2 (0.2)	2 (0.2)
	Emergency room	4 (1.3)	19 (5.7)	5 (2.1)	9 (2.1)	37 (2.8)	28 (3.1)
Type of AF Diagnosed, n(%)	n (missing)	317 (0)	334 (0)	241 (0)	420 (0)	1312 (0)	892 (0)
	Permanent	4 (1.3)	8 (2.4)	12 (5.0)	89 (21.2)	113 (8.6)	24 (2.7)
	Persistent	32 (10.1)	48 (14.4)	19 (7.9)	41 (9.8)	140 (10.7)	99 (11.1)
	Paroxysmal	60 (18.9)	50 (15.0)	37 (15.4)	76 (18.1)	223 (17.0)	147 (16.5)
	New	221 (69.7)	228 (68.3)	173 (71.8)	214 (51.0)	836 (63.7)	622 (69.7)

**Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : INDIA**

Variable	Statistics	Cohort 2 (N=317) (n %)	Cohort 3 (N=334) (n %)	Cohort 4 (N=241) (n %)	Cohort 5 (N=420) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1312)	Total Prospective patients Cohorts 1 to 4 (N=892)
Treatment Costs, n(%)	n (missing)	224 (0)	222 (0)	166 (0)	302 (0)	914 (0)	612 (0)
	Public insurance	23 (10.3)	8 (3.6)	4 (2.4)	8 (2.6)	43 (4.7)	35 (5.7)
	Private (insurance)	12 (5.4)	9 (4.1)	7 (4.2)	47 (15.6)	75 (8.2)	28 (4.6)
	Private (out of pocket)	186 (83.0)	198 (89.2)	154 (92.8)	241 (79.8)	779 (85.2)	538 (87.9)
	Combination	3 (1.3)	7 (3.2)	1 (0.6)	6 (2.0)	17 (1.9)	11 (1.8)
	Unknown	93	112	75	118	398	280
Treatment Sector, n(%)	n (missing)	307 (0)	323 (0)	228 (0)	407 (0)	1265 (0)	858 (0)
	In the public sector	40 (13.0)	58 (18.0)	43 (18.9)	59 (14.5)	200 (15.8)	141 (16.4)
	In the private sector	267 (87.0)	265 (82.0)	185 (81.1)	348 (85.5)	1065 (84.2)	717 (83.6)
	Unknown	10	11	13	13	47	34

**Table 05 : Vital signs and life style
Full Analysis Dataset : INDIA**

Variable	Statistics	Cohort 2 (N=317) (n %)	Cohort 3 (N=334) (n %)	Cohort 4 (N=241) (n %)	Cohort 5 (N=420) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1312)	Total Prospective patients Cohorts 1 to 4 (N=892)
Height (cm)	n (missing)	233 (84)	248 (86)	152 (89)	282 (138)	915 (397)	633 (259)
	Mean (SD)	162.9 (8.6)	161.2 (9.5)	163.1 (8.5)	162.0 (9.1)	162.2 (9.0)	162.3 (9.0)
	Median (IQR)	164.0 (157.0 to 168.0)	160.0 (155.0 to 168.0)	164.0 (160.0 to 168.0)	162.0 (156.0 to 168.0)	163.0 (157.0 to 168.0)	163.0 (157.0 to 168.0)
	Min to Max	132 to 183	122 to 191	130 to 183	137 to 198	122 to 198	122 to 191
Weight (kg)	n (missing)	233 (84)	248 (86)	152 (89)	282 (138)	915 (397)	633 (259)
	Mean (SD)	64.0 (11.6)	63.5 (13.4)	63.4 (10.4)	64.4 (12.5)	63.9 (12.2)	63.6 (12.1)
	Median (IQR)	64.0 (57.0 to 71.0)	63.0 (55.0 to 71.5)	63.5 (56.0 to 70.0)	63.0 (56.0 to 71.0)	63.0 (55.0 to 71.0)	64.0 (55.0 to 71.0)
	Min to Max	35 to 114	32 to 121	42 to 96	40 to 110	32 to 121	32 to 121
BMI (kg/m ²)	n (missing)	233 (84)	248 (86)	152 (89)	282 (138)	915 (397)	633 (259)
	Mean (SD)	24.1 (4.0)	24.5 (5.1)	23.9 (4.1)	24.6 (4.1)	24.3 (4.4)	24.2 (4.5)
	Median (IQR)	24.0 (22.0 to 26.0)	24.0 (22.0 to 27.0)	24.0 (21.0 to 26.0)	24.0 (22.0 to 26.0)	24.0 (22.0 to 26.0)	24.0 (22.0 to 26.0)
	Min to Max	14 to 40	13 to 47	14 to 36	12 to 40	12 to 47	13 to 47
BMI Category, n(%)	n (missing)	233 (84)	248 (86)	152 (89)	282 (138)	915 (397)	633 (259)
	<19	20 (8.6)	27 (10.9)	11 (7.2)	15 (5.3)	73 (8.0)	58 (9.2)
	19-<25	122 (52.4)	114 (46.0)	87 (57.2)	156 (55.3)	479 (52.3)	323 (51.0)
	25-<30	74 (31.8)	80 (32.3)	39 (25.7)	86 (30.5)	279 (30.5)	193 (30.5)
	30-<40	17 (7.3)	24 (9.7)	15 (9.9)	24 (8.5)	80 (8.7)	56 (8.8)
	>=40	-	3 (1.2)	-	1 (0.4)	4 (0.4)	3 (0.5)
Pulse (bpm)	n (missing)	305 (12)	324 (10)	233 (8)	408 (12)	1270 (42)	862 (30)
	Mean (SD)	93.5 (27.4)	98.6 (25.3)	95.3 (28.8)	99.9 (29.9)	97.2 (28.1)	95.9 (27.1)
	Median (IQR)	85.0 (74.0 to 106.0)	94.0 (80.0 to 111.0)	86.0 (74.0 to 116.0)	92.0 (79.0 to 123.0)	90.0 (77.0 to 114.0)	88.0 (76.0 to 110.0)
	Min to Max	40 to 196	40 to 185	37 to 180	33 to 210	33 to 210	37 to 196

**Table 05 : Vital signs and life style
Full Analysis Dataset : INDIA**

Variable	Statistics	Cohort 2 (N=317) (n %)	Cohort 3 (N=334) (n %)	Cohort 4 (N=241) (n %)	Cohort 5 (N=420) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1312)	Total Prospective patients Cohorts 1 to 4 (N=892)
Systolic BP (mm Hg)	n (missing)	311 (6)	327 (7)	236 (5)	411 (9)	1285 (27)	874 (18)
	Mean (SD)	130.5 (21.0)	128.0 (22.2)	131.3 (19.9)	130.4 (21.4)	130.0 (21.2)	129.8 (21.2)
	Median (IQR)	130.0 (120.0 to 140.0)	130.0 (110.0 to 140.0)	130.0 (120.0 to 140.0)	130.0 (120.0 to 140.0)	130.0 (120.0 to 140.0)	130.0 (118.0 to 140.0)
	Min to Max	70 to 200	60 to 216	90 to 200	70 to 240	60 to 240	60 to 216
Diastolic BP (mm Hg)	n (missing)	311 (6)	327 (7)	236 (5)	411 (9)	1285 (27)	874 (18)
	Mean (SD)	80.6 (11.8)	79.3 (12.5)	80.3 (11.2)	79.8 (11.1)	79.9 (11.7)	80.0 (11.9)
	Median (IQR)	80.0 (70.0 to 90.0)	80.0 (70.0 to 90.0)	80.0 (70.0 to 90.0)	80.0 (70.0 to 90.0)	80.0 (70.0 to 90.0)	80.0 (70.0 to 90.0)
	Min to Max	50 to 140	50 to 130	48 to 120	50 to 120	48 to 140	48 to 140
LVEF (%)	n (missing)	172 (145)	238 (96)	153 (88)	298 (122)	861 (451)	563 (329)
	Mean (SD)	47.4 (15.8)	48.8 (13.4)	50.8 (13.6)	50.0 (14.2)	49.3 (14.3)	48.9 (14.3)
	Median (IQR)	55.0 (35.0 to 60.0)	53.0 (40.0 to 60.0)	55.0 (45.0 to 60.0)	55.0 (40.0 to 60.0)	55.0 (38.0 to 60.0)	55.0 (38.0 to 60.0)
	Min to Max	15 to 80	15 to 83	15 to 74	15 to 77	15 to 83	15 to 83
LVEF Category, n (n%)	n (missing)	172 (145)	238 (96)	153 (88)	298 (122)	861 (451)	563 (329)
	<40%	58 (33.7)	58 (24.4)	30 (19.6)	74 (24.8)	220 (25.6)	146 (25.9)
	>=40%	114 (66.3)	180 (75.6)	123 (80.4)	224 (75.2)	641 (74.4)	417 (74.1)
History of Hypertension, n(%)	n (missing)	317 (0)	330 (0)	238 (0)	417 (0)	1302 (0)	885 (0)
	No	86 (27.1)	100 (30.3)	69 (29.0)	149 (35.7)	404 (31.0)	255 (28.8)
	Yes	231 (72.9)	230 (69.7)	169 (71.0)	268 (64.3)	898 (69.0)	630 (71.2)

Table 05 : Vital signs and life style
Full Analysis Dataset : INDIA

Variable	Statistics	Cohort 2 (N=317) (n %)	Cohort 3 (N=334) (n %)	Cohort 4 (N=241) (n %)	Cohort 5 (N=420) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1312)	Total Prospective patients Cohorts 1 to 4 (N=892)
	Unknown	-	4	3	3	10	7
Alcohol Consumption, n(%)	n (missing)	212 (0)	220 (0)	204 (0)	290 (0)	926 (0)	636 (0)
	Abstinent	183 (86.3)	186 (84.5)	168 (82.4)	243 (83.8)	780 (84.2)	537 (84.4)
	Light	24 (11.3)	28 (12.7)	24 (11.8)	23 (7.9)	99 (10.7)	76 (11.9)
	Moderate	4 (1.9)	4 (1.8)	10 (4.9)	18 (6.2)	36 (3.9)	18 (2.8)
	Heavy	1 (0.5)	2 (0.9)	2 (1.0)	6 (2.1)	11 (1.2)	5 (0.8)
	Unknown	105	114	37	130	386	256
Smoker, n(%)	n (missing)	248 (0)	270 (0)	210 (0)	342 (0)	1070 (0)	728 (0)
	No	220 (88.7)	229 (84.8)	158 (75.2)	294 (86.0)	901 (84.2)	607 (83.4)
	Ex-smoker	16 (6.5)	28 (10.4)	35 (16.7)	27 (7.9)	106 (9.9)	79 (10.9)
	Current smoker	12 (4.8)	13 (4.8)	17 (8.1)	21 (6.1)	63 (5.9)	42 (5.8)
	Unknown	69	64	31	78	242	164

Table 06 : Clinical History
Full Analysis Dataset : INDIA

Variable	Statistics	Cohort 2 (N=317) (n %)	Cohort 3 (N=334) (n %)	Cohort 4 (N=241) (n %)	Cohort 5 (N=420) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1312)	Total Prospective patients Cohorts 1 to 4 (N=892)
Congestive heart failure, n(%)	n (missing)	317 (0)	334 (0)	241 (0)	420 (0)	1312 (0)	892 (0)
	No	271 (85.5)	272 (81.4)	200 (83.0)	357 (85.0)	1100 (83.8)	743 (83.3)
	Yes	46 (14.5)	62 (18.6)	41 (17.0)	63 (15.0)	212 (16.2)	149 (16.7)
Congestive Heart Failure NYHA Class, n(%)	n (missing)	40 (271)	56 (272)	33 (200)	47 (357)	176 (1100)	129 (743)
	I	3 (7.5)	1 (1.8)	3 (9.1)	3 (6.4)	10 (5.7)	7 (5.4)
	II	23 (57.5)	28 (50.0)	10 (30.3)	11 (23.4)	72 (40.9)	61 (47.3)
	III	6 (15.0)	20 (35.7)	18 (54.5)	26 (55.3)	70 (39.8)	44 (34.1)
	IV	8 (20.0)	7 (12.5)	2 (6.1)	7 (14.9)	24 (13.6)	17 (13.2)
	Unknown	6	6	8	16	36	20
Coronary artery disease, n(%)	n (missing)	317 (0)	334 (0)	241 (0)	420 (0)	1312 (0)	892 (0)
	No	240 (75.7)	226 (67.7)	172 (71.4)	306 (72.9)	944 (72.0)	638 (71.5)
	Yes	77 (24.3)	108 (32.3)	69 (28.6)	114 (27.1)	368 (28.0)	254 (28.5)
Acute coronary syndrome, n(%)	n (missing)	317 (0)	325 (0)	234 (0)	412 (0)	1288 (0)	876 (0)
	No	281 (88.6)	291 (89.5)	205 (87.6)	375 (91.0)	1152 (89.4)	777 (88.7)
	Yes	36 (11.4)	34 (10.5)	29 (12.4)	37 (9.0)	136 (10.6)	99 (11.3)
	Unknown	-	9	7	8	24	16
Carotid Occlusive Disease, n(%)	n (missing)	317 (0)	328 (0)	236 (0)	408 (0)	1289 (0)	881 (0)
	No	316 (99.7)	320 (97.6)	235 (99.6)	406 (99.5)	1277 (99.1)	871 (98.9)

Table 06 : Clinical History
Full Analysis Dataset : INDIA

Variable	Statistics	Cohort 2 (N=317) (n %)	Cohort 3 (N=334) (n %)	Cohort 4 (N=241) (n %)	Cohort 5 (N=420) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1312)	Total Prospective patients Cohorts 1 to 4 (N=892)
	Yes	1 (0.3)	8 (2.4)	1 (0.4)	2 (0.5)	12 (0.9)	10 (1.1)
	Unknown	-	6	5	12	23	11
PE or DVT, n(%)	n (missing)	317 (0)	329 (0)	239 (0)	411 (0)	1296 (0)	885 (0)
	No	316 (99.7)	324 (98.5)	234 (97.9)	402 (97.8)	1276 (98.5)	874 (98.8)
	Yes	1 (0.3)	5 (1.5)	5 (2.1)	9 (2.2)	20 (1.5)	11 (1.2)
	Unknown	-	5	2	9	16	7
Other Thromboemboli sm, n(%)	n (missing)	311 (6)	0 (334)	0 (241)	0 (420)	311 (1001)	311 (581)
	No	310 (99.7)	-	-	-	310 (99.7)	310 (99.7)
	Yes	1 (0.3)	-	-	-	1 (0.3)	1 (0.3)
Systemic Embolization, n(%)	n (missing)	317 (0)	329 (0)	238 (0)	407 (0)	1291 (0)	884 (0)
	No	317 (100.0)	326 (99.1)	237 (99.6)	402 (98.8)	1282 (99.3)	880 (99.5)
	Yes	-	3 (0.9)	1 (0.4)	5 (1.2)	9 (0.7)	4 (0.5)
	Unknown	-	5	3	13	21	8
Coronary Artery Bypass Graft, n(%)	n (missing)	317 (0)	330 (0)	240 (0)	413 (0)	1300 (0)	887 (0)
	No	308 (97.2)	318 (96.4)	233 (97.1)	394 (95.4)	1253 (96.4)	859 (96.8)
	Yes	9 (2.8)	12 (3.6)	7 (2.9)	19 (4.6)	47 (3.6)	28 (3.2)
	Unknown	-	4	1	7	12	5
Stroke/TIA, n(%)	n (missing)	317 (0)	334 (0)	241 (0)	420 (0)	1312 (0)	892 (0)

Table 06 : Clinical History
Full Analysis Dataset : INDIA

Variable	Statistics	Cohort 2 (N=317) (n %)	Cohort 3 (N=334) (n %)	Cohort 4 (N=241) (n %)	Cohort 5 (N=420) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1312)	Total Prospective patients Cohorts 1 to 4 (N=892)
	No	285 (89.9)	305 (91.3)	218 (90.5)	381 (90.7)	1189 (90.6)	808 (90.6)
	Yes	32 (10.1)	29 (8.7)	23 (9.5)	39 (9.3)	123 (9.4)	84 (9.4)
Stroke, n(%)	n (missing)	317 (0)	325 (0)	239 (0)	410 (0)	1291 (0)	881 (0)
	No	296 (93.4)	313 (96.3)	222 (92.9)	396 (96.6)	1227 (95.0)	831 (94.3)
	Yes	21 (6.6)	12 (3.7)	17 (7.1)	14 (3.4)	64 (5.0)	50 (5.7)
	Unknown	-	9	2	10	21	11
History of Bleeding, n(%)	n (missing)	317 (0)	329 (0)	237 (0)	407 (0)	1290 (0)	883 (0)
	No	314 (99.1)	326 (99.1)	235 (99.2)	394 (96.8)	1269 (98.4)	875 (99.1)
	Yes	3 (0.9)	3 (0.9)	2 (0.8)	13 (3.2)	21 (1.6)	8 (0.9)
	Unknown	-	5	4	13	22	9
Hypercholester olaemia, n(%)	n (missing)	317 (0)	291 (0)	215 (0)	368 (0)	1191 (0)	823 (0)
	No	272 (85.8)	262 (90.0)	176 (81.9)	312 (84.8)	1022 (85.8)	710 (86.3)
	Yes	45 (14.2)	29 (10.0)	39 (18.1)	56 (15.2)	169 (14.2)	113 (13.7)
	Unknown	-	43	26	52	121	69
Diabetes, n(%)	n (missing)	317 (0)	334 (0)	241 (0)	420 (0)	1312 (0)	892 (0)
	No	217 (68.5)	203 (60.8)	139 (57.7)	284 (67.6)	843 (64.3)	559 (62.7)
	Type I	-	16 (4.8)	6 (2.5)	3 (0.7)	25 (1.9)	22 (2.5)
	Type II	100 (31.5)	115 (34.4)	96 (39.8)	133 (31.7)	444 (33.8)	311 (34.9)
Diabetes, n(%)	n (missing)	317 (0)	334 (0)	241 (0)	420 (0)	1312 (0)	892 (0)
	No	217 (68.5)	203 (60.8)	139 (57.7)	284 (67.6)	843 (64.3)	559 (62.7)
	Yes	100 (31.5)	131 (39.2)	102 (42.3)	136 (32.4)	469 (35.7)	333 (37.3)
Cirrhosis, n(%)	n (missing)	317 (0)	326 (0)	233 (0)	402 (0)	1278 (0)	876 (0)
	No	315 (99.4)	325 (99.7)	233 (100.0)	397 (98.8)	1270 (99.4)	873 (99.7)

Table 06 : Clinical History
Full Analysis Dataset : INDIA

Variable	Statistics	Cohort 2 (N=317) (n %)	Cohort 3 (N=334) (n %)	Cohort 4 (N=241) (n %)	Cohort 5 (N=420) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1312)	Total Prospective patients Cohorts 1 to 4 (N=892)
	Yes	2 (0.6)	1 (0.3)	-	5 (1.2)	8 (0.6)	3 (0.3)
	Unknown	-	8	8	18	34	16
Dementia, n(%)	n (missing)	317 (0)	330 (0)	238 (0)	412 (0)	1297 (0)	885 (0)
	No	314 (99.1)	329 (99.7)	233 (97.9)	406 (98.5)	1282 (98.8)	876 (99.0)
	Yes	3 (0.9)	1 (0.3)	5 (2.1)	6 (1.5)	15 (1.2)	9 (1.0)
	Unknown	-	4	3	8	15	7
Hyperthyroidism, n(%)	n (missing)	317 (0)	307 (0)	213 (0)	380 (0)	1217 (0)	837 (0)
	No	315 (99.4)	304 (99.0)	211 (99.1)	373 (98.2)	1203 (98.8)	830 (99.2)
	Yes	2 (0.6)	3 (1.0)	2 (0.9)	7 (1.8)	14 (1.2)	7 (0.8)
	Unknown	-	27	28	40	95	55
Hypothyroidism, n(%)	n (missing)	317 (0)	305 (0)	213 (0)	380 (0)	1215 (0)	835 (0)
	No	295 (93.1)	281 (92.1)	203 (95.3)	346 (91.1)	1125 (92.6)	779 (93.3)
	Yes	22 (6.9)	24 (7.9)	10 (4.7)	34 (8.9)	90 (7.4)	56 (6.7)
	Unknown	-	29	28	40	97	57
Vascular Disease, n(%)	n (missing)	317 (0)	324 (10)	236 (5)	414 (6)	1291 (21)	877 (15)
	No	278 (87.7)	269 (83.0)	198 (83.9)	361 (87.2)	1106 (85.7)	745 (84.9)
	Yes	39 (12.3)	55 (17.0)	38 (16.1)	53 (12.8)	185 (14.3)	132 (15.1)
Moderate to Severe CKD, n(%)	n (missing)	317 (0)	334 (0)	241 (0)	420 (0)	1312 (0)	892 (0)
	No	303 (95.6)	321 (96.1)	217 (90.0)	400 (95.2)	1241 (94.6)	841 (94.3)
	Yes	14 (4.4)	13 (3.9)	24 (10.0)	20 (4.8)	71 (5.4)	51 (5.7)

Study ID: TRI08888

GARFIELD: International Registry of Patients Newly Diagnosed with AF

**Table 06 : Clinical History
Full Analysis Dataset : INDIA**

**Table 07 : Treatment for stroke prophylaxis
Full Analysis Dataset : INDIA**

Variable	Statistics	Cohort 2 (N=317) (n %)	Cohort 3 (N=334) (n %)	Cohort 4 (N=241) (n %)	Cohort 5 (N=420) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1312)	Total Prospective patients Cohorts 1 to 4 (N=892)
Baseline Treatment, n(%)	n (missing)	314 (0)	332 (0)	241 (0)	418 (0)	1305 (0)	887 (0)
	VKA	39 (12.4)	37 (11.1)	25 (10.4)	38 (9.1)	139 (10.7)	101 (11.4)
	VKA+AP	63 (20.1)	65 (19.6)	65 (27.0)	68 (16.3)	261 (20.0)	193 (21.8)
	FXA	2 (0.6)	-	5 (2.1)	3 (0.7)	10 (0.8)	7 (0.8)
	FXA+AP	-	1 (0.3)	9 (3.7)	8 (1.9)	18 (1.4)	10 (1.1)
	DTI	4 (1.3)	9 (2.7)	6 (2.5)	9 (2.2)	28 (2.1)	19 (2.1)
	DTI+AP	3 (1.0)	4 (1.2)	7 (2.9)	8 (1.9)	22 (1.7)	14 (1.6)
	AP	137 (43.6)	147 (44.3)	73 (30.3)	192 (45.9)	549 (42.1)	357 (40.2)
	NONE	66 (21.0)	69 (20.8)	51 (21.2)	92 (22.0)	278 (21.3)	186 (21.0)
	Unknown	3	2	-	2	7	5
	VKA±AP	102 (32.5)	102 (30.7)	90 (37.3)	106 (25.4)	400 (30.7)	294 (33.1)
	FXA±AP	2 (0.6)	1 (0.3)	14 (5.8)	11 (2.6)	28 (2.1)	17 (1.9)
	DTI±AP	7 (2.2)	13 (3.9)	13 (5.4)	17 (4.1)	50 (3.8)	33 (3.7)
	FXA/DTI	6 (1.9)	9 (2.7)	11 (4.6)	12 (2.9)	38 (2.9)	26 (2.9)
	FXA/DTI+AP	3 (1.0)	5 (1.5)	16 (6.6)	16 (3.8)	40 (3.1)	24 (2.7)
	FXA/DTI±AP	9 (2.9)	14 (4.2)	27 (11.2)	28 (6.7)	78 (6.0)	50 (5.6)
	AC	45 (14.3)	46 (13.9)	36 (14.9)	50 (12.0)	177 (13.6)	127 (14.3)
	AC+AP	66 (21.0)	70 (21.1)	81 (33.6)	84 (20.1)	301 (23.1)	217 (24.5)
	AC±AP	111 (35.4)	116 (34.9)	117 (48.5)	134 (32.1)	478 (36.6)	344 (38.8)

Table 08: Treatment
Full Analysis Dataset : INDIA

	Cohort 2 (N=317) (n %)	Cohort 3 (N=334) (n %)	Cohort 4 (N=241) (n %)	Cohort 5 (N=420) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1312)	Total Prospective patients Cohorts 1 to 4 (N=892)
Anti-platelet (non mutually exclusive groups)						
Glycoprotein inhibitors	4 (1.3)	2 (0.6)	-		6 (0.5)	6 (0.7)
ADP receptor/P2Y12 inhibitors	82 (25.9)	104 (31.1)	47 (19.5)	63 (15.0)	296 (22.6)	233 (26.1)
Prostaglandin Cox inhibitors	1 (0.3)	-	-		1 (0.1)	1 (0.1)
ASA	-	43 (12.9)	21 (8.7)	41 (9.8)	105 (8.0)	64 (7.2)
	149 (47.0)	135 (40.4)	112 (46.5)	199 (47.4)	595 (45.4)	396 (44.4)
Anticoagulant drugs (non mutually exclusive groups)						
VKA	104 (32.8)	104 (31.1)	90 (37.3)	108 (25.7)	406 (30.9)	298 (33.4)
FXa	4 (1.3)	3 (0.9)	14 (5.8)	11 (2.6)	32 (2.4)	21 (2.4)
DTI	8 (2.5)	15 (4.5)	13 (5.4)	19 (4.5)	55 (4.2)	36 (4.0)
Heparinoid	1 (0.3)	3 (0.9)	-	2 (0.5)	6 (0.5)	4 (0.4)
Heparins	38 (12.0)	78 (23.4)	31 (12.9)	99 (23.6)	246 (18.8)	147 (16.5)
Other	8 (2.5)	10 (3.0)	6 (2.5)	29 (6.9)	53 (4.0)	24 (2.7)

Table 09 : Risk scores
Full Analysis Dataset : INDIA

Variable	Statistics	Cohort 2 (N=317) (n %)	Cohort 3 (N=334) (n %)	Cohort 4 (N=241) (n %)	Cohort 5 (N=420) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1312)	Total Prospective patients Cohorts 1 to 4 (N=892)
CHADS2 Score	n (missing)	315 (2)	327 (7)	236 (5)	413 (7)	1291 (21)	878 (14)
	Mean (SD)	1.8 (1.1)	1.8 (1.0)	1.8 (1.1)	1.6 (1.2)	1.7 (1.1)	1.8 (1.0)
	Median (IQR)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)
	Min to Max	0 to 6	0 to 5	0 to 5	0 to 6	0 to 6	0 to 6
CHADS2 score categories, n(%)	n (missing)	315 (2)	327 (7)	236 (5)	413 (7)	1291 (21)	878 (14)
	0	29 (9.2)	29 (8.9)	20 (8.5)	64 (15.5)	142 (11.0)	78 (8.9)
	1	115 (36.5)	100 (30.6)	79 (33.5)	142 (34.4)	436 (33.8)	294 (33.5)
	2	104 (33.0)	133 (40.7)	91 (38.6)	129 (31.2)	457 (35.4)	328 (37.4)
	3	44 (14.0)	52 (15.9)	28 (11.9)	50 (12.1)	174 (13.5)	124 (14.1)
	4	19 (6.0)	10 (3.1)	15 (6.4)	17 (4.1)	61 (4.7)	44 (5.0)
	5	3 (1.0)	3 (0.9)	3 (1.3)	9 (2.2)	18 (1.4)	9 (1.0)
	6	1 (0.3)	-	-	2 (0.5)	3 (0.2)	1 (0.1)
CHA2DS2- VASc Score	n (missing)	315 (2)	317 (17)	230 (11)	402 (18)	1264 (48)	862 (30)
	Mean (SD)	2.9 (1.5)	3.1 (1.4)	3.0 (1.5)	2.9 (1.6)	3.0 (1.5)	3.0 (1.5)
	Median (IQR)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)
	Min to Max	0 to 9	0 to 7	0 to 6	0 to 8	0 to 9	0 to 9
CHA2DS2- VASc score categories, n(%)	n (missing)	315 (2)	317 (17)	230 (11)	402 (18)	1264 (48)	862 (30)
	0	8 (2.5)	9 (2.8)	8 (3.5)	25 (6.2)	50 (4.0)	25 (2.9)
	1	51 (16.2)	34 (10.7)	31 (13.5)	56 (13.9)	172 (13.6)	116 (13.5)
	2	81 (25.7)	67 (21.1)	53 (23.0)	84 (20.9)	285 (22.5)	201 (23.3)
	3	62 (19.7)	90 (28.4)	60 (26.1)	99 (24.6)	311 (24.6)	212 (24.6)
	4	65 (20.6)	68 (21.5)	39 (17.0)	73 (18.2)	245 (19.4)	172 (20.0)

Table 09 : Risk scores
Full Analysis Dataset : INDIA

Variable	Statistics	Cohort 2 (N=317) (n %)	Cohort 3 (N=334) (n %)	Cohort 4 (N=241) (n %)	Cohort 5 (N=420) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1312)	Total Prospective patients Cohorts 1 to 4 (N=892)
	5	30 (9.5)	33 (10.4)	25 (10.9)	43 (10.7)	131 (10.4)	88 (10.2)
	6-9	18 (5.7)	16 (5.0)	14 (6.1)	22 (5.5)	70 (5.5)	48 (5.6)
HAS-BLED score	n (missing)	114 (203)	195 (139)	192 (49)	275 (145)	776 (536)	501 (391)
	Mean (SD)	1.6 (0.9)	1.5 (0.8)	1.5 (1.0)	1.5 (0.9)	1.5 (0.9)	1.5 (0.9)
	Median (IQR)	2.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)
	Min to Max	0 to 4	0 to 4	0 to 5	0 to 4	0 to 5	0 to 5
HAS-BLED score categories, n(%)	n (missing)	114 (203)	195 (139)	192 (49)	275 (145)	776 (536)	501 (391)
	0	8 (7.0)	17 (8.7)	30 (15.6)	32 (11.6)	87 (11.2)	55 (11.0)
	1	46 (40.4)	82 (42.1)	73 (38.0)	102 (37.1)	303 (39.0)	201 (40.1)
	2	42 (36.8)	80 (41.0)	65 (33.9)	109 (39.6)	296 (38.1)	187 (37.3)
	3	17 (14.9)	15 (7.7)	19 (9.9)	30 (10.9)	81 (10.4)	51 (10.2)
	4	1 (0.9)	1 (0.5)	4 (2.1)	2 (0.7)	8 (1.0)	6 (1.2)
	5	-	-	1 (0.5)	-	1 (0.1)	1 (0.2)

Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : INDIA

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 2	0	-	-	2	25	-	-	-	-	-	-	-	-	4	50	2	25	-
	1	4	7.8	6	11.8	-	-	-	-	-	-	-	-	24	47.1	17	33.3	-
	2	11	13.8	13	16.3	-	-	-	-	1	1.3	-	-	39	48.8	16	20	1
	3	12	19.4	12	19.4	1	1.6	-	-	1	1.6	-	-	22	35.5	14	22.6	-
	4	6	9.4	20	31.3	1	1.6	-	-	-	-	1	1.6	26	40.6	10	15.6	1
	5	4	13.3	7	23.3	-	-	-	-	1	3.3	2	6.7	12	40	4	13.3	-
6-9	1	5.9	3	17.6	-	-	-	-	1	5.9	-	-	9	52.9	3	17.6	1	
Cohort 3	0	1	11.1	1	11.1	-	-	-	-	-	-	-	-	7	77.8	-	-	-
	1	1	2.9	5	14.7	-	-	-	-	1	2.9	-	-	15	44.1	12	35.3	-
	2	12	17.9	9	13.4	-	-	1	1.5	1	1.5	1	1.5	30	44.8	13	19.4	-
	3	14	15.7	17	19.1	-	-	-	-	5	5.6	-	-	34	38.2	19	21.3	1
	4	4	6	19	28.4	-	-	-	-	1	1.5	2	3	27	40.3	14	20.9	1
	5	3	9.1	6	18.2	-	-	-	-	-	-	1	3	18	54.5	5	15.2	-
6-9	1	6.3	6	37.5	-	-	-	-	1	6.3	-	-	7	43.8	1	6.3	-	
Cohort 4	0	1	12.5	-	-	-	-	1	12.5	-	-	-	-	2	25	4	50	-
	1	3	9.7	6	19.4	1	3.2	2	6.5	-	-	-	-	8	25.8	11	35.5	-
	2	7	13.2	14	26.4	-	-	-	-	1	1.9	1	1.9	16	30.2	14	26.4	-
	3	6	10	21	35	3	5	2	3.3	1	1.7	-	-	21	35	6	10	-
	4	6	15.4	12	30.8	-	-	1	2.6	3	7.7	2	5.1	10	25.6	5	12.8	-
	5	1	4	8	32	-	-	-	-	1	4	1	4	9	36	5	20	-
6-9	-	-	3	21.4	1	7.1	3	21.4	-	-	2	14.3	4	28.6	1	7.1	-	
Cohort 5	0	1	4	4	16	-	-	-	-	-	-	-	-	9	36	11	44	-
	1	5	9.1	5	9.1	-	-	-	-	1	1.8	-	-	30	54.5	14	25.5	1
	2	8	9.5	15	17.9	1	1.2	1	1.2	4	4.8	4	4.8	36	42.9	15	17.9	-
	3	7	7.1	16	16.2	1	1	3	3	2	2	2	2	38	38.4	30	30.3	-
	4	12	16.4	12	16.4	-	-	-	-	-	-	1	1.4	38	52.1	10	13.7	-
	5	2	4.8	8	19	-	-	1	2.4	-	-	-	-	21	50	10	23.8	1
6-9	1	4.5	6	27.3	1	4.5	3	13.6	1	4.5	-	-	9	40.9	1	4.5	-	

Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : INDIA

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Total Prospective patients Cohorts 1 to 5	0	3	6	7	14	-	-	1	2	-	-	-	-	22	44	17	34	-
	1	13	7.6	22	12.9	1	0.6	2	1.2	2	1.2	-	-	77	45	54	31.6	1
	2	38	13.4	51	18	1	0.4	2	0.7	7	2.5	6	2.1	121	42.6	58	20.4	1
	3	39	12.6	66	21.3	5	1.6	5	1.6	9	2.9	2	0.6	115	37.1	69	22.3	1
	4	28	11.5	63	25.9	1	0.4	1	0.4	4	1.6	6	2.5	101	41.6	39	16	2
	5	10	7.7	29	22.3	-	-	1	0.8	2	1.5	4	3.1	60	46.2	24	18.5	1
	6-9	3	4.3	18	26.1	2	2.9	6	8.7	3	4.3	2	2.9	29	42	6	8.7	1
Total Prospective patients Cohorts 1 to 4	0	2	8	3	12	-	-	1	4	-	-	-	-	13	52	6	24	-
	1	8	6.9	17	14.7	1	0.9	2	1.7	1	0.9	-	-	47	40.5	40	34.5	-
	2	30	15	36	18	-	-	1	0.5	3	1.5	2	1	85	42.5	43	21.5	1
	3	32	15.2	50	23.7	4	1.9	2	0.9	7	3.3	-	-	77	36.5	39	18.5	1
	4	16	9.4	51	30	1	0.6	1	0.6	4	2.4	5	2.9	63	37.1	29	17.1	2
	5	8	9.1	21	23.9	-	-	-	-	2	2.3	4	4.5	39	44.3	14	15.9	-
	6-9	2	4.3	12	25.5	1	2.1	3	6.4	2	4.3	2	4.3	20	42.6	5	10.6	1

Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : INDIA

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	
Cohort 2	0	4	50	-	-	-	-	-	-	-	-	-	-	-	-	-	4	50	-
	1	6	13.3	11	24.4	2	4.4	-	-	-	-	-	-	24	53.3	2	4.4	1	
	2	1	2.4	13	31	-	-	-	-	-	-	-	-	28	66.7	-	-	-	
	3	-	-	4	23.5	-	-	-	-	-	-	1	5.9	12	70.6	-	-	-	
	4-9	-	-	1	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cohort 3	0	7	41.2	-	-	-	-	-	-	1	5.9	-	-	-	-	9	52.9	-	
	1	9	11.1	13	16	-	-	-	-	4	4.9	-	-	35	43.2	20	24.7	1	
	2	2	2.5	20	25	-	-	1	1.3	3	3.8	3	3.8	48	60	3	3.8	-	
	3	-	-	4	26.7	-	-	-	-	-	-	-	-	11	73.3	-	-	-	
	4-9	-	-	1	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cohort 4	0	9	30	-	-	1	3.3	-	-	1	3.3	-	-	-	-	19	63.3	-	
	1	7	9.6	19	26	1	1.4	2	2.7	2	2.7	-	-	22	30.1	20	27.4	-	
	2	6	9.2	26	40	-	-	2	3.1	1	1.5	1	1.5	26	40	3	4.6	-	
	3	-	-	8	42.1	1	5.3	2	10.5	-	-	2	10.5	6	31.6	-	-	-	
	4-9	-	-	4	80	-	-	-	-	-	-	1	20	-	-	-	-	-	
Cohort 5	0	8	25	-	-	1	3.1	-	-	1	3.1	-	-	-	-	22	68.8	-	
	1	11	10.9	15	14.9	1	1	1	1	2	2	2	2	44	43.6	25	24.8	1	
	2	4	3.7	32	29.6	-	-	2	1.9	-	-	4	3.7	61	56.5	5	4.6	1	
	3	1	3.3	9	30	-	-	2	6.7	1	3.3	-	-	15	50	2	6.7	-	
	4-9	-	-	-	-	-	-	1	50	-	-	-	-	1	50	-	-	-	
Total Prospective patients Cohorts 1 to 5	0	28	32.2	-	-	2	2.3	-	-	3	3.4	-	-	-	-	54	62.1	-	
	1	33	11	58	19.3	4	1.3	3	1	8	2.7	2	0.7	125	41.7	67	22.3	3	
	2	13	4.4	91	30.8	-	-	5	1.7	4	1.4	8	2.7	163	55.3	11	3.7	1	
	3	1	1.2	25	30.9	1	1.2	4	4.9	1	1.2	3	3.7	44	54.3	2	2.5	-	

**Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : INDIA**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	
	4-9	-	-	6	66.7	-	-	1	11.1	-	-	1	11.1	1	11.1	-	-	-	-
Total Prospective patients Cohorts 1 to 4	0	20	36.4	-	-	1	1.8	-	-	2	3.6	-	-	-	-	32	58.2	-	
	1	22	11.1	43	21.6	3	1.5	2	1	6	3	-	-	81	40.7	42	21.1	2	
	2	9	4.8	59	31.6	-	-	3	1.6	4	2.1	4	2.1	102	54.5	6	3.2	-	
	3	-	-	16	31.4	1	2	2	3.9	-	-	3	5.9	29	56.9	-	-	-	
	4-9	-	-	6	85.7	-	-	-	-	-	-	1	14.3	-	-	-	-	-	

**Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : INDIA**

Variable	Statistics	Cohort 2 (N=102) (n %)	Cohort 3 (N=102) (n %)	Cohort 4 (N=90) (n %)	Total Prospective patients Cohorts 1 to 4 (N=294)
TTR value, n(%)	n (missing)	8 (94)	11 (91)	9 (81)	28 (266)
	<65	7 (87.5)	10 (90.9)	8 (88.9)	25 (89.3)
	>=65	1 (12.5)	1 (9.1)	1 (11.1)	3 (10.7)
TTR	n (missing)	8 (94)	11 (91)	9 (81)	28 (266)
	Mean (SD)	35.8 (23.9)	22.5 (22.9)	20.1 (26.0)	25.5 (24.2)
	Median (IQR)	32.3 (22.3 to 48.8)	17.3 (0.0 to 34.2)	14.4 (0.0 to 25.0)	22.3 (0.0 to 40.4)
	Min to Max	0.0 to 79.2	0.0 to 67.5	0.0 to 75.1	0.0 to 79.2
INR value, n(%)	n	47	51	56	154
	2-3	15 (31.9)	12 (23.5)	10 (17.9)	37 (24.0)
	<2	23 (48.9)	33 (64.7)	43 (76.8)	99 (64.3)
	>3	9 (19.1)	6 (11.8)	3 (5.4)	18 (11.7)
INR	n	47	51	56	154
	Mean (SD)	2.2 (0.9)	2.1 (1.7)	1.7 (0.7)	2.0 (1.2)
	Median (IQR)	2.0 (1.6 to 2.8)	1.5 (1.3 to 2.2)	1.4 (1.3 to 1.8)	1.6 (1.3 to 2.3)
	Min to Max	0.8 to 5.3	1.0 to 12.6	1.1 to 4.0	0.8 to 12.6

**Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : INDIA**

Outcome	Cause	N	Events	Event rate /100 person-years	95% CI
All-cause death		892	81	9.85	(7.92 to 12.25)
	Cardiovascular death	892	36	4.38	(3.16 to 6.07)
	Non-Cardiovascular death	892	15	1.82	(1.10 to 3.03)
	Undetermined cause	892	30	3.65	(2.55 to 5.22)
Stroke/SE		892	9	1.10	(0.57 to 2.11)
Major bleed		892	3	0.37	(0.12 to 1.13)
Acute coronary syndrome		892	4	0.49	(0.18 to 1.29)
Congestive Heart Failure		892	6	0.73	(0.33 to 1.63)

**Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : INDIA**

		INDIA		
Outcome	Cause	N	Events	%
Cardiovascular causes	Myocardial infarction	36	6	16.67
	Ischaemic stroke	36	2	5.56
	Congestive heart failure	36	10	27.78
	Sudden or unwitnessed death	36	9	25.00
	Other	36	9	25.00
Non-cardiovascular causes	Accidental / trauma	15	1	6.67
	Respiratory failure	15	3	20.00
	Infection/sepsis	15	1	6.67
	Malignancy	15	1	6.67
	Other	15	9	60.00

**Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset :INDIA**

OUTCOME	INDIA		
	N	Events	%
Stroke(not including systemic embolism)	892	9	1.01
Primary Ischemic Stroke	892	6	0.67
Primary intracerebral hemorrhage*	892	1	0.11
<i>Intracerebral</i>	892	1	0.11
Undetermined	892	2	0.22

**Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : INDIA**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	25	24.43	1	4.09	(0.58 to 29.06)
1	116	109.28	4	3.66	(1.37 to 9.75)
2	201	192.91	9	4.67	(2.43 to 8.97)
3	212	191.36	25	13.06	(8.83 to 19.33)
4+	308	275.47	39	14.16	(10.34 to 19.38)
Unknown	30	28.81	3	10.42	(3.36 to 32.29)

**Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : INDIA**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	25	24.43	0	-	-
1	116	109.28	0	-	-
2	201	191.63	3	1.57	(0.51 to 4.85)
3	212	191.25	1	0.52	(0.07 to 3.71)
4+	308	275.26	5	1.82	(0.76 to 4.36)
Unknown	30	28.81	0	-	-

**Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : INDIA**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	25	24.43	0	-	-
1	116	109.28	0	-	-
2	201	192.91	0	-	-
3	212	191.36	1	0.52	(0.07 to 3.71)
4+	308	275.47	2	0.73	(0.18 to 2.90)
Unknown	30	28.81	0	-	-